- Sun Pharma reported a 3rd quarter net income of 29 billion rupees, marking a 15% increase year-over-year, slightly above the estimated 28.77 billion rupees.
- The company’s revenue reached 136.8 billion rupees, an increase of 11% compared to the previous year, beating the estimate of 133.78 billion rupees.
- India sales reached 43.00 billion rupees, surpassing the estimated 42.08 billion rupees.
- US revenue was reported at $474 million, which was below the expected $508.2 million.
- Revenue from Emerging Markets was $277 million, exceeding the estimate of $267.3 million.
- Sales from the Rest of the World came in at $259 million, significantly higher than the estimated $206.4 million.
- Sales of Active Pharmaceutical Ingredients were 5.68 billion rupees, closely aligned with the estimate of 5.67 billion rupees.
- The investor consensus includes 30 buy recommendations, 7 hold recommendations, and 4 sell recommendations.
Sun Pharmaceutical Industries on Smartkarma
Analysts on Smartkarma, such as Tina Banerjee, have been closely following Sun Pharmaceutical Industries. In a recent report titled “Sun Pharmaceutical (SUNP IN): Q2 Result Beats Estimate; Specialty Business to Face Growth Challenge,” it was highlighted that Sun Pharma’s Q2FY25 net profit saw a significant 28% year-on-year increase alongside an 11% growth in revenue. However, concerns were raised regarding the specialty business segment, which is facing growth challenges due to the deferral of clinical trials. The report also mentioned a cut in the company’s R&D investment guidance for FY25, reflecting the uncertainties in the specialty product pipeline.
The analysis pointed out that without immediate drivers like the Leqselvi launch and with some products still in late-stage trials, Sun Pharmaceutical’s specialty business momentum is lacking. The report underscores the importance of keeping a close eye on how Sun Pharma navigates these challenges to drive future growth in its specialty segment. This detailed insight provides investors and stakeholders valuable information on the company’s financial performance and strategic outlook in the competitive pharmaceutical industry.
A look at Sun Pharmaceutical Industries Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, Sun Pharmaceutical Industries has a positive long-term outlook. With high scores in Dividend, Growth, Resilience, and Momentum, the company is positioned well for the future. Sun Pharmaceutical Industries manufactures and markets pharmaceuticals globally, focusing on areas such as diabetes, cardiology, neurology, psychiatry, and gastroenterology.
The company’s strong scores in Dividend, Growth, Resilience, and Momentum indicate that Sun Pharmaceutical Industries is performing well across various key factors. Investors may find the company attractive due to its solid performance in these areas, suggesting a promising future ahead. Sun Pharmaceutical Industries‘ diverse pharmaceutical portfolio positions it as a strong player in the industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
